Tag Archives: Zydus Cadila

Zydus Cadila gets USFDA nod to market high blood-pressure treatment drug

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Stock Exchanges in India on Monday, Ahmedabad headquartered Zydus Cadila Group (Cadila Healthcare) said of having received the final approval from the USFDA (United States Food & Drugs Administration) to market Chlorthalidone Tablets USP (US RLD – THALITONE@),25 mg and 50 mg.

Zydus Cadila (Healthcare) gets USFDA nod to market anti-epileptic drug to prevent & control seizures

AHMEDABAD-GANDHINAGAR | MUMBAI | RAJKOT – In a press-release submitted to the Indian Bourses on Monday, Ahmedabad headquartered pharma major – Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) has received the tentative approval from the USFDA to market Lacosamide Tablets (US RLD – Vimpat®) in the strengths of 50 mg, 100 mg,

USFDA concludes Cadila Healthcare’s (Zydus) Pharmez facility with one observation

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Bourses, on Wednesday, Ahmedabad headquartered Pharma major Cadila Healthcare (Dr Pankaj Patel led Zydus Cadila Group) Ltd said of one of their units being inspected by US Food & Drugs Administration (USFDA) and the regulator has concluded the inspection with one

Cadila Healthcare (Zydus) gets USFDA nod to market tabs to cure urniery tract disorders

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Bourses, Ahmedabad headquartered Zydus Cadila has received the tentative approval from the USFDA to market Mirabegron Extended-Release Tablets (US RLD- Myrbetriq® Extended-Release Tablets), 25 mg and 50 mg. Mirabegron is selective beta 3-adrenoceptor agonist approved for the treatment of Overactive Bladder

Zydus Cadila gets USFDA nod, to market tablets, to treat high blood-pressure in lungs

AHMEDABAD | MUMBAI | RAJKOT – In a press-release submitted to the Indian Bourses, Ahmedabad headquartered pharma major – Cadila Healthcare Ltd (Dr Pankaj Patel owned Zydus Cadila Group) said of having received final approval from the US Food & Drugs Administration (USFDA) for Ambrisentan Tablets. The Company has received the final approval from the

Zydus Cadila gets USFDA nod to market erectile dysfunction treatment tabs

AHMEDABAD | MUMBAI | RAJKOT – Zydus Cadila announced the Day 1 launch of Tadalafil Tablets USP (US RLD – Cialis Tablets) upon receiving the final approval from the US FDA for marketing the product in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. Manufactured at the group’s manufacturing facility at Moraiya,

USFDA inspects Zydus Cadila’s subsidiary co, issues one observation

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Bourses, Ahmedabad headquartered Cadila Healthcare Ltd said of its USFDA conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac Pharmaceuticals Ltd., the injectable onco manufacturing facility, located at Pharmez, Ahmedabad from 18th to 26th March, 2019.

Zydus Cadila gets USFDA nod to market drugs to treat cholesterol and body tissues

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Exchanges in India, Ahmedabad headquartered and Dr Pankaj Patel led Cadila Healthcare Ltd (Zydus Cadila Group) said of having got US Food & Drugs Administration’s nod to market drug two drugs, one to control cholesterol as well another to treat abnormal hardening

Zydus Cadila gets USFDA nod to market drug to treat excess iron levels in human blood

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Exchanges on Tuesday, Ahmedabad headquartered and Pankaj Patel owned Cadila Healthcare (Zydus Cadila Group) said of having got US Food and Drugs Administration nod to market drug to treat excess iron levels in human blood. Zydus Cadila has received the tentative

Zydus Cadila gets US FDA nod to market drug for treatment of epilepsy

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Bourses on Tuesday, Cadila Healthcare Ltd (Dr Pankaj Patel owned Zydus Cadila group) said of having availed regulatory approval from US Food and Drugs Administration (USFDA) to market drug to treat epilepsy. Zydus Cadila has received the final approval from the

Zydus Cadila gets US FDA nod to market anti-arthritis drug

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Bourses on Thursday, Ahmedabad headquartered and Dr Pankaj Patel led Cadila Healthcare Ltd (Zydus Cadila Group) said of having received regulatory approvals from US FDA (Food & Drugs Department) to market anti-arthritis drug. Zydus Cadila has received the tentative approval from

Zydus Cadila gets US FDA nod to market osteoporosis, ortho treatment drug

MUMBAI | AHMEDABAD | RAJKOT – Dr Pankaj Patel led and Ahmedabad headquartered Zydus Cadila Group (Cadila Healthcare Ltd) has received final approval from the US regulators to market ortho treatment medicine, the company said in a press release submitted to the Indian Bourses, today. Zydus Cadila has received the final approval from the USFDA

Zydus Cadila keen to set-up mfg facility at Hyderabad, reports Telangana Today

HYDERABAD | AHMEDABAD | RAJKOT – Ahmedabad headquartered and Dr Pankaj Patel led Zydus Cadila Group (Cadila Healthcare Ltd) is keen to establish setting-up a facility in the upcoming Hyderabad Pharma City, Telengana Today reports Quoting Dr Pankaj Patel as told to Telengana Today, the report said of Cadila Healthcare in future to surely look

Zydus Cadila gets US FDA nod to market tablets for diabetic care

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Bourses on Tuesday, Dr Pankaj Patel led Zydus Cadila group (Cadila Healthcare Ltd.) said of having got approval from US FDA (Food & Drugs Administration) to market Sitagliptin Tablets in dosage value of 25 mg (milligram), 50 mg and 100 mg.

Zydus Cadila gets USFDA nod to market anti-viral drug

AHMEDABAD | MUMBAI | RAJKOT – Dr Pankaj Patel led Zydus Cadila Group got US FDA (Food and Drugs Administration) nod to market anti-viral drug Acyclovir Sodium Injection in composition of 500 mg and 1,000 mg, Cadila Healthcare Ltd said today, in a press release submitted to the Exchanges in India. Zydus Cadila has received

Zydus Cadila to pay 1.56 billion rupees to acquires 51% stake in Windlass Healthcare

AHMEDABAD | MUMBAI | RAJKOT – Zydus Cadila Group will pay 1.55 billion (~155.55 crore) rupees to acquire 51% stake in Dehradun (Uttarakhand) headquartered Windlas Healthcare Pvt Ltd, the company press release submitted to the Exchanges in India on Monday read. The acquisition detailing regulatory document submitted to the exchange termed the objective of the